pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·13h ago·1 min read
save

Postpartum psychiatry remains inadequately understood, case of Lindsay Clancy highlights gaps

Aug 12, 2026·read at STAT ↗Negative

The opinion piece, authored by a neuroscience professor at Tufts, an obstetrics‑psychiatry specialist at NewYork‑Presbyterian and Weill Cornell, and a psychiatry researcher at the University of Virginia, examines the high‑profile Lindsay Clancy case.

The authors argue that the tragic deaths of three children and their mother expose how limited current treatment options are, how difficult diagnosis can be, and how much of the science remains unfinished. They contend that the medical community still lacks a robust understanding of postpartum psychiatric illnesses.

Beyond the courtroom, the case underscores a broader challenge for clinicians and researchers: the need for better diagnostic tools and more effective therapies to protect mothers and families during the postpartum period.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: The Lindsay Clancy case shows the limits of postpartum psychiatry”

read at STAT ↗
1,079 words · retrieved 13h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Virginia3Ultragenyx Pharmaceutical Inc.
topics
Psychiatry & CNS14Major Depression5Women's Health2GLP-1 receptorHematologyObesityRare DiseaseVaccines

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series BFierce Biotech
  • Jul 18Opinion: STAT readers on the value of primary care, obesity as a disease, and moreSTAT
  • Jun 8Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or restSTAT
  • Jun 5Texas AG investigating energy drinksSTAT